{'fraction_non_alphanumeric': 0.023255813953488372, 'fraction_numerical': 0.012028869286287089, 'mean_word_length': 5.5, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Use of insulin glargine during pregnancy

Background. Good metabolic control maintained throughout pregnancy reduces maternal and fetal complications in diabetic women. The long‐acting insulin analogue glargine has 24‐h persistence and a peakless action profile, and could contribute to more stable daily plasma glucose levels and improved glycemic control. We evaluated the metabolic control associated with insulin glargine during pregnancy in comparison with conventional basal insulin therapy. Methods. Retrospective case‐control analysis of glycemic control and pregnancy complications in 100 type 1 diabetic pregnancies with intermediate‐acting NPH insulin or insulin glargine prior to conception and throughout pregnancy. Results. Overall, glycemic control was not different between the groups, though the decrease in HbA1c from the first to the third trimester was greater with insulin glargine (0.8 versus 0.3%, p = 0.04). The rate of hypoglycemia was comparable. Conclusions. Our findings suggest that, as regards metabolic control, insulin glargine in women with type 1 diabetes is comparable with NPH insulin as basal insulin therapy. No adverse effects were associated with glargine use at the time of conception and during pregnancy.